164 related articles for article (PubMed ID: 35332180)
1. HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy.
Álvarez B; Navarrete-Muñoz MA; Briz V; Olmedillas-López S; Nistal S; Cabello A; Prieto L; Górgolas M; García-Arranz M; Benito JM; Rallón N
Sci Rep; 2022 Mar; 12(1):5095. PubMed ID: 35332180
[TBL] [Abstract][Full Text] [Related]
2. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic HCV genotype 1 coinfection.
Boesecke C; Rockstroh JK
Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
[TBL] [Abstract][Full Text] [Related]
4. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
Townsend K; Meissner EG; Sidharthan S; Sampson M; Remaley AT; Tang L; Kohli A; Osinusi A; Masur H; Kottilil S
AIDS Res Hum Retroviruses; 2016 May; 32(5):456-62. PubMed ID: 26559180
[TBL] [Abstract][Full Text] [Related]
5. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Lacombe JM; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L; ; Martinez V
HIV Med; 2021 Nov; 22(10):924-935. PubMed ID: 34402547
[TBL] [Abstract][Full Text] [Related]
6. Impact of HCV eradication with direct-acting antiviral agents on serum gamma globulin levels in HCV and HCV/HIV coinfected patients.
Milazzo L; van den Bogaart L; Sollima S; Oreni L; Lai A; Morena V; Bonazzetti C; Ridolfo Anna L; Antinori S
Eur J Intern Med; 2020 May; 75():50-54. PubMed ID: 31980330
[TBL] [Abstract][Full Text] [Related]
7. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.
Poveda E; Vispo E; Barreiro P; de Mendoza C; Labarga P; Fernández-Montero JV; Martin-Carbonero L; Soriano V
Antivir Ther; 2012; 17(3):571-5. PubMed ID: 22293607
[TBL] [Abstract][Full Text] [Related]
8. Mental disorders in HIV/HCV coinfected patients under antiviral treatment for hepatitis C.
Martin-Subero M; Diez-Quevedo C
Psychiatry Res; 2016 Dec; 246():173-181. PubMed ID: 27718466
[TBL] [Abstract][Full Text] [Related]
9. HCV treatment in Sardinian HIV-HCV coinfected patients: a real-life perspective study on safety, efficacy, and immune reconstitution.
Pes F; Onali S; Balestrieri C; Angioni G; Ortu F; Piano P; Lucia B; Scioscia R; Princic E; Bolliri AC; Casale M; Cola A; Conti M; Peddis L; Serra G; Vacca S; Loi M; Urru E; Murru C; Matta L; Del Giacco S; Babudieri S; Maida I; Chessa L
Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1509-1516. PubMed ID: 36173889
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world.
Uriarte-Pinto M; Navarro-Aznarez H; De La Llama-Celis N; Arazo-Garcés P; Martínez-Sapiña AM; Abad-Sazatornil MR
Int J Clin Pharm; 2018 Jun; 40(3):608-616. PubMed ID: 29556931
[TBL] [Abstract][Full Text] [Related]
11. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
[TBL] [Abstract][Full Text] [Related]
12. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication.
Chromy D; Mandorfer M; Bucsics T; Schwabl P; Bauer D; Scheiner B; Schmidbauer C; Lang GF; Szekeres T; Ferenci P; Trauner M; Reiberger T
AIDS Patient Care STDS; 2019 May; 33(5):197-206. PubMed ID: 31067123
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
[TBL] [Abstract][Full Text] [Related]
15. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
[TBL] [Abstract][Full Text] [Related]
16. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
Rodríguez-Torres M
Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341
[TBL] [Abstract][Full Text] [Related]
17. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Rockstroh JK; Ingiliz P; Petersen J; Peck-Radosavljevic M; Welzel TM; Van der Valk M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
Antivir Ther; 2017; 22(3):225-236. PubMed ID: 27845298
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).
Ingiliz P; Christensen S; Kimhofer T; Hueppe D; Lutz T; Schewe K; Busch H; Schmutz G; Wehmeyer MH; Boesecke C; Simon KG; Berger F; Rockstroh JK; Schulze zur Wiesch J; Baumgarten A; Mauss S
Clin Infect Dis; 2016 Nov; 63(10):1320-1324. PubMed ID: 27535952
[TBL] [Abstract][Full Text] [Related]
19. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
[TBL] [Abstract][Full Text] [Related]
20. HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials.
Shafran SD
Clin Infect Dis; 2015 Oct; 61(7):1127-34. PubMed ID: 26060286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
